The relevance of our findings to human cancer is reflected by the fact that high level of SOX2 protein expression is associated with a poor patient survival in a cohort of stage II pancreatic cancer patients following gemcitabine treatment. This evidence concerns the gene SOX2 and familial pancreatic carcinoma.